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Abstract Genetic susceptibility testing for common diseases
is expanding, but little is known about race group differences
in test perceptions. The purpose of this study was to examine
differences between African Americans and Whites in
knowledge, attitudes, and motivations regarding genetic
susceptibility testing for Alzheimer’s disease (AD). Before
enrolling in an AD genetic testing research trial, 313 first-
degree relatives of AD patients (20% African American; 71%
female; mean age = 58 years) were surveyed regarding:
(1) knowledge about genetics and AD risk; (2) concerns
about developing AD; and (3) reasons for seeking testing.
In comparison to Whites, African Americans were less
knowledgeable about genetics and AD risk (p<.01) and less
concerned about developing AD (p<.05), with lower levels
of perceived disease risk (p=.04). The results suggest that
African Americans and Whites differ notably in their
knowledge, beliefs, and attitudes regarding genetic testing
for AD. Additional research with more representative
samples is needed to better understand these differences.
Keywords Genetic testing . African Americans .
Alzheimer’s disease . APOE . Risk assessment .
Susceptibility testing . Health beliefs . Health literacy .
Health disparities
Introduction
The number of people with Alzheimer’s disease (AD) has
nearly doubled since 1980, with greater than four million
Americans living with the disease (Alzheimer’s Association
2008). Genetic tests that identify individual susceptibility to
several common adult-onset diseases, including AD, are now
commercially available, and medical advances in genetic
research on AD have brought about the possibility of genetic
susceptibility testing for asymptomatic individuals (Masters
and Beyreuther 1998; Peters et al. 2004; Roses 1997).
Susceptibility alleles are distinct from Mendelian variations
for conditions such as Huntington’s disease in that they are
typically more prevalent but much less strongly associated
with disease expression (Farrer et al. 1995b). The Apolipo-
protein (APOE) ε4 allele on chromosome 19 is a well-
established genetic risk factor for AD (Kim et al. 2009).
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Limitations in test sensitivity and specificity coupled with
the lack of treatment options for the disorder have prompted
concerns about introducing this type of genetic testing for
AD into clinical practice (AGSEC 2001; Farrer et al. 1995a;
McConnell et al. 1998; NIA et al. 1996; Post et al. 1997).
However, predictive testing is already available for families
with rare early-onset forms of AD (Lennox et al. 1994) and
susceptibility testing, along with predictive testing using
neuroimaging results and other biomarkers, may one day
become a viable option for the millions of first-degree
relatives of patients with AD who are at increased risk for
developing this disease (Roberts and Tersegno 2010).
There is some evidence that the incidence of AD, the
impact of risk factors causing the disease, and the impact of
family history may differ between African Americans and
Whites (Farrer et al. 1997; Gurland et al. 1999; Tang et al.
1998, 2001). A focus has been placed on African
Americans due to recent research suggesting that this group
is at heightened risk for developing AD in comparison to
Whites (Green et al. 2002). Epidemiological studies have
consistently supported a higher age specific prevalence of
dementia (Gurland et al. 1999), higher cumulative risk of
AD (Tang et al. 1998) and higher incidence rates of AD
(Tang et al. 2001) among African Americans compared
with Whites. The ε4 allele is an important risk factor for
AD in African Americans, particularly among those
younger than 70 years of age (Graff-Radford et al. 2002).
It has been suggested that APOE information can be used in
a research setting to offer genetic counseling to family
members of patients with AD (Green 2002).
Clinical research suggests Whites are far more likely than
ethnic minorities to pursue genetic counseling and genetic
susceptibility testing (Armstrong et al. 2005) for conditions
such as hereditary breast and ovarian cancer syndrome, and
that this disparity may be attributable to differences in
exposure to genetic information and referrals by health care
providers (Hughes et al. 2003). However, there has been little
research done on race/ethnic group differences in attitudes
toward, and interest in genetic susceptibility testing. To date,
only a few studies have been conducted in this area, and
most have relied on hypothetical test scenarios as opposed to
actual test situations (Neumann et al. 2001; Roberts 2000). In
a study done by Hipps et al. (2003), attitudes toward genetic
testing for AD were investigated in a racially diverse sample,
with African Americans showing less interest in testing,
endorsing fewer reasons for pursuing it, and anticipating
fewer negative consequences from a positive test result than
their White counterparts. Conversely, a telephone survey
conducted by Singer et al. (2004), found that Latinos and
African Americans were more likely to express preferences
for prenatal and adult genetic testing in comparison to
Whites. Reasons for these differences are not fully under-
stood but may be attributable to the different sampling
techniques and survey methods employed by these studies.
The current study represents a real-life genetic testing
situation with a sample of participants who volunteered to
receive APOE results and genetic susceptibility information
related to AD. The purpose of this study was to investigate
race group differences in knowledge about and attitudes
towards genetic testing prior to receiving standardized
education that was provided as part of the protocol.
Methods
Participants and Procedures
Data utilized in this analysis were from the second in a series
of randomized controlled clinical trials, known as the
REVEAL (Risk Evaluation and Education for Alzheimer’s
Disease) Study, investigating the impact of risk assessment in
asymptomatic family members of AD patients. In this study,
adult children and siblings of patients with AD received
education, genetic counseling and risk assessments regarding
their own chances of developing AD. Participants were given
personalized risk information based on their age, race, gender,
family history of AD, and APOE genotype (Cupples et al.
2004). The study was conducted with Institutional Review
Board approval at four sites including: Boston University,
Case Western Reserve University, Weill Medical College of
Cornell University and Howard University. Most study
participants heard about the REVEAL Study through the
media, the Internet, other research studies, public presenta-
tions, or word-of-mouth. A few participants were recruited
through AD research registries at the participating sites, or
while attending memory assessment clinics with their
affected family member.
Adults over the age of 18 who had one living or deceased
first-degree relative with AD were eligible for this study.
Individuals who had more than one affected first-degree
relative were excluded from the study, as risk estimates were
not developed for that higher-risk population. Additionally, we
excluded individuals with first-degree relatives who devel-
oped the disease before the age of 60 given the study’s focus
on risk for late-onset AD. Individuals over the age of 85 were
also excluded because there were insufficient data to produce
AD risk estimates beyond the age of 85.
Project staff members, who were primarily master’s level
research assistants trained in study procedures, collected
basic demographic information from potential participants
by telephone in order to assess their study eligibility prior
to enrollment in the REVEAL Study. Eligible individuals
then proceeded to the second step of the study where
informed consent was obtained; more detailed demographic
information was collected, and knowledge and attitudes
regarding AD, genetics, and personal risk of developing
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AD (including most of the data for this paper) were
assessed. Participants willing to proceed further into the
study were then randomized into one of two different
education and AD risk disclosure arms. Data used in this
study were collected on an individual basis over a 3-year
period. Primary outcomes of this randomized trial will be
reported elsewhere and are not addressed in this paper.
Measures
Knowledge
At baseline, participants were asked four general knowl-
edge questions (see Table 2) regarding AD and genetic
testing developed as part of a study of a racially diverse
sample of older adults in the Boston and Birmingham, AL
areas (Moscarillo et al. 2007). Responses to each question
were analyzed and correct responses were then individually
summed to create an overall knowledge score ranging from
0 to 4.
Concern About AD
At baseline, participants were also asked five questions
over the phone regarding their concern about developing
AD (see Table 3). These questions were drawn from prior
work on attitudes toward genetic testing for AD, including
a large community-based survey in the Southeast that
oversampled African Americans (Green 2002; Roberts
2000). Participants were asked to indicate the extent to
which they agreed with each item using a 5-point Likert
type scale (1 = “strongly disagree” to 5 = “strongly agree”)
and each of the five items were examined independently.
Additionally, we dichotomized (1 = agree; 0 = did not
agree) responses to each question by grouping answers of
agreement (i.e. 1 = participants responded “somewhat
agree” or “strongly agree”) versus answers of “neutral” or
disagreement (i.e., “somewhat disagree,” or “strongly
disagree”). In a separate analysis, participants were also
asked to provide a numerical estimate of what they thought
their chances were of developing AD throughout their
lifetime, rating their estimates by choosing a number
between 0 and 100%.
Reasons for and Against Seeking Genetic Susceptibility
Testing
Prior to attending their education session, participants were
asked to rate the importance of twelve possible reasons why
they might seek genetic risk assessment for AD (Table 4)
(Roberts et al. 2003). These reasons covered personal,
family, altruistic, pragmatic and financial motivations.
Participants were also asked to rate the importance of ten
possible reasons not to seek genetic testing for AD (Table 5).
Reasons offered included unwanted distress and emotional
reactions, lack of definitive results, lack of a cure or
prevention medication, and others. Both scales demonstrat-
ed a high level of internal consistency reliability in the
current study (Cronbach alpha = 0.82 for reasons for
seeking testing scale, 0.81 for reasons against seeking
testing scale).
Participants were asked to indicate how important the
listed factors were to them personally by using a 5-point
scale (1 = “not at all important” to 5 = “extremely important”);
these items were analyzed individually. Dichotomous
responses (1 = important vs. 0 = not important) were created
by grouping responses indicating the question was important
(1 = “very important” or “extremely important”) vs. neutral or
not important. These dichotomized responses were used to
create summed scores representing the total number of reasons
endorsed for and against seeking genetic testing.
General Anxiety
The Beck Anxiety Inventory (BAI) is a 21-item measure
designed to distinguish common symptoms of anxiety from
those of depression and to be sensitive to treatment change
(Beck et al. 1988). It has been extensively validated and has
shown excellent test-retest reliability and internal validity
(Wetherell and Arean 1997). The BAI is scored on the basis
of self-reported severity of a given symptom over the past
week from 0 (not at all) to 3 (severe), yielding a total score
from 0 to 63.
Data Analysis
All analyses were conducted using SAS 9.1 software.
Descriptive statistics were used to characterize sample
demographics and responses on individual survey items.
Chi-square analyses were used to examine race group
differences on categorical items. Analyses of covariance
were used to examine race group differences on continuous
summed items adjusting for the following covariates: age,
gender, years of education [range: 0 (no formal education)
to 20 (doctoral degree)], and baseline BAI score. Logistic
regression analyses were performed on the dichotomized
individual items on (a) the AD concern scale, (b) the
reasons for seeking genetic testing scale, and (c) the reasons
against testing scale, adjusting for the same covariates listed
above. Income level was not included as a covariate given
its collinearity with education level. Additionally, including
income would require removing a significant number of
participants with missing income responses, thus decreasing
our sample size and statistical power. A post hoc analysis
among subsamples matched by socioeconomic status
assessing ethnic group differences between participants in
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a low SES vs. a high SES group produced results following
the same trends we observed in analyzing the total sample
(data not shown).
Results
Demographics
A total of 313 African American and White participants were
enrolled in the study at the pre-education stage (See Table 1),
after excluding 7 participants with other race and 9
participants with missing responses (response rate 97%
among participants at pre-education). All of these partic-
ipants were adult children or siblings of persons with AD,
and the majority of participants were White (80%), female
(71%) and college-educated (mean = 16 years of education).
Most participants were in a high median income bracket
($70,000–99,000), and had health insurance upon entering
the study (96%).
Of the 313 participants, 20% (n=64) were African
American, and there were significant demographic distinc-
tions between the two race groups (see Table 1). African
Americans differed from Whites in years of education,
gender distribution, and income level. African Americans
had lower mean education levels (mean = 15.0 years, SD=
3.0, vs. mean = 16.2 years, SD=2.4, t(84.16)=−3.05, p<.01),
were more likely to be female (86% vs. 68%, #2ð1`Þ ¼ 8:48,
p<.01), and had lower income status in comparison to
Whites (median = $50,000–69,999 vs. median = $70,000–
99,999, #2ð5Þ ¼ 31:28, p<.01). The group comparison on
income excluded the 20 participants (90% of whom were
White) with missing data on this survey item.
Knowledge
A summary of participant responses on the knowledge scale
can be found in Table 2. The adjusted mean population
knowledge score for the entire sample was 2.3 (out of a
possible 4); however, there were significant race group
differences with Whites scoring higher than African
Americans (2.5 vs. 1.8, F(1,279)=14.52, p<.001). Our
results suggest that Whites were more likely to know: (1)
the APOE genetic test does not predict AD with certainty
(#2ð1Þ ¼ 17:99, p<.0001); (2) the average person’s lifetime
risk of AD is 10–15% (#2ð1Þ ¼ 5:01, p=0.03); and (3) being
APOE ε4 positive only makes the chances of developing
AD somewhat higher (#2ð1Þ ¼ 9:12, p<.01). Fewer than half
of African Americans correctly answered three of the four
knowledge questions, while 62% of Whites answered
questions correctly. The question most commonly answered
incorrectly by both groups was “What is the average
person’s lifetime risk of getting AD?” (52% correct
responses overall).
Table 1 Sample demographics
Demographic characteristics African Americans (n=64) Whites (n=249) Total sample (N=313)
Mean Age, Years (SD); 58.6 (10.4) 58.0 (10.8) 58.1 (10.7)
Range 36–86 33–86 33–86
Sexa
Female. #(%) 55 (86%) 168 (68%) 223 (71%)
Male, #, (%) 9 (14%) 81 (32%) 90 (29%)
Mean years of education (SD)b 15.0 (3.0) 16.2 (2.4) 16.0 (2.6)
Range 3–20 7–20 3–20
Site, # participants (%)
Boston University 9 (14%) 92 (37%) 101 (32%)
Cornell 2 (3%) 84 (34%) 86 (28%)
Case Western 6 (9%) 63 (25%) 69 (22%)
Howard 47 (73%) 10 (4%) 57 (18%)
Median income bracketb $50,000–69,999 $70,000–99,999 $70,000–99,999
Health insurance
# (%) w/health insurance 60 (94%) 240 (96%) 300 (96%)
# (%) w/out health insurance 4 (6%) 9 (4%) 13 (4%)
Long term care (LTC) insurance
# (%) w/LTC insurance 15 (23%) 55 (22%) 70 (22%)
# (%) w/out LTC insurance 49 (77%) 194 (78%) 243 (78%)
a African American > White; p<.01
bWhite > African American; p<.01
Attitudes, Beliefs and Knowledge Regarding Genetic Testing for AD 653
A closer look at the data showed significant differences
in how African Americans and Whites answered some of
these knowledge questions. African Americans were more
likely to choose the “undecided” response when asked if the
APOE genetic test can predict with certainty whether a
person will get AD(#2ð1Þ ¼ 7:18, p<.01).
Perceived Concern
A summary of participant responses on the AD concern
scale can be found in Table 3. Because of a low reliability
score on this scale, (Cronbach alpha <.60) we analyzed
individual items only. Seventy-five percent of all partic-
ipants endorsed (i.e., marked “somewhat agree” or “strong-
ly agree”) items indicating concern about developing AD;
however a significantly greater percentage of Whites
endorsed this statement in comparison to African Ameri-
cans (77% vs. 63%, #2ð1Þ ¼ 5:31, p<.05). Multivariate
logistic regression analyses also suggested that women
were more concerned than men (#2ð1Þ ¼ 13:23, p<.001) and
that younger age (#2ð1Þ ¼ 8:11, p<.01) was associated with
higher concern. Race group differences were not found for
any of the other items measuring concern (Table 6).
With regard to participants’ quantitative estimates of
perceived lifetime risk of developing AD, the estimated
adjusted group mean was 56.8%. Race group differences
were found as Whites estimated a higher lifetime chance of
developing AD than African Americans (57.4 vs. 49.7,
F(1,279)=6.02, p<0.05), despite being at lower objective
risk as a group (Cupples et al. 2004). The average lifetime
risk ultimately disclosed to Whites was 32.9%, compared to
54.5% for African Americans.
Reasons for Seeking Genetic Testing
A summary of participant responses on this scale can be
found in Table 4. Greater than 60% of respondents endorsed
as “very” or “extremely important” five of the possible
twelve reasons for seeking genetic testing. The most
commonly endorsed reasons were: (1) to know more about
my risk in case better treatments become available (84%);
(2) to seek information on preventive measures (82%); (3)
Table 2 Participant responses to knowledge items on questionnaire
Questionnaire items (response choices, with correct answer in bold) African Americans
(n=64)
Whites
(n=249)
Total sample
(N=313)
% Responding correctly
Can the APOE genetic test predict with certainty whether one will get AD?a 28% 58% 52%
(Yes; no; undecided)
What is the average person’s lifetime risk of getting AD?a 36% 52% 48%
(>75%; 45–50%; 10–15%; 1–5%)
How are people’s chances of developing AD different if they have an
affected parent or sibling?
70% 75% 74%
(the same as everyone else; somewhat higher than people in general;
much higher than people in general)
How does having APOE ε4 affect one’s chances of getting AD?a 40% 62% 57%
(there is no effect, makes one somewhat more likely to get AD, makes
one much more likely to get AD)
Mean knowledge items answered correctly, out of four (SD)a 1.8 (1.1) 0–4 2.5 (1.1) 0–4 2.3 (1.1) 0–4
aWhite > African American; p<.05
Table 3 Participant responses on perceived concern about Alzheimer’s disease scale
Scale items African Americans
(n=64)
Whites
(n=249)
Total sample
(N=313)
% “Agree” or “Strongly agree”
I am concerned that I’ll develop ADa 63% 77% 74%
I am concerned that I will develop AD in the next 5 years 20% 16% 17%
I’d like to know if I am going to develop AD at some point in my life 88% 91% 90%
I believe that I will develop AD 33% 42% 40%
AD is the worst disease I can think of 52% 49% 49%
aWhite > African American; p<.05
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the desire to contribute to research on AD (77%); (4) the
need to arrange my personal affairs (64%); and (5) the need
to make arrangements for my long-term care (63%).
Participants endorsed as “very/extremely important” an
average of 6.5 out of 11 reasons for seeking genetic testing
for AD. On average, African Americans and Whites
endorsed roughly the same amount of reasons for testing
(6.8 vs. 6.3). As Table 4 indicates, African Americans and
Whites differed on numerous items; however, after adjust-
ing for covariates in our multivariate analyses, the only
difference that remained statistically significant was that
African Americans were more likely to endorse “to confirm
the feeling that I might already be developing AD”
(#2ð1Þ ¼ 4:46, p=.03). Greater than 80% of all participants
identified “the need to know of personal risk in case better
treatment became available,” and “the need to seek
information on preventative measures,” as important rea-
sons for seeking genetic susceptibility testing.
Table 4 Participant ratings of importance of reasons for seeking genetic testing
Questionnaire items African Americans
(n=64)
Whites
(n=249)
Total sample
(N=313)
% Endorsing as very or extremely important
The need to prepare my family for my possible illness 65% 54% 56%
The need to arrange my personal affairs 66% 63% 64%
The desire to start doing things sooner than I had planned to 47% 48% 48%
To know more about my risk in case better treatments become available 84% 84% 84%
The need to make arrangements for my long-term care 61% 64% 63%
To give information about my children’s possible risk of AD 66% 46% 51%
The desire to contribute to research 84% 76% 78%
To put my mind at ease if I found out I was not at risk for AD 63% 49% 51%
To confirm the feeling that I might already be developing ADa 42% 21% 25%
To plan for suicide if I test positive 0% 1% 1%
To seek information on preventative measures 84% 82% 82%
Curiosity 61% 39% 44%
Mean items endorsed (SD) 6.8 (3.2) 6.3 (1.1) 6.5 (2.9)
Range 0–11 0–11 0–11
a African American > White; p<.05
Table 5 Participant importance ratings of reasons against seeking genetic testing questionnaire
Questionnaire items African Americans
(n=64)
Whites
(n=249)
Total sample
(N=313)
% Endorsing as very or extremely important
It would be too upsetting to find out I’m at risk for ADa 19% 8% 11%
The test does not give me a definite answer about whether or not I might get AD 15% 10% 11%
The test procedure would be too burdensome 3% 3% 3%
It could make me worry about my children’s risk of getting AD 13% 8% 9%
The test results might upset my loved ones 17% 10% 12%
The results could affect my health insuranceb 16% 29% 26%
The results could change how people look at or act towards me 8% 10% 10%
The results could affect my employment 14% 9% 10%
There is no way to cure or prevent ADa 26% 13% 15%
My family does not think it is a good idea for me 2% 3% 3%
Mean items endorsed (SD) 1.2 (1.9) 1.1 (1.6) 1.1 (1.6)
Range 0–9 0–8 0–9
a African American > White; p<.05
bWhite > African American; p<.05
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Reasons Against Seeking Genetic Testing
A summary of participant responses to items on the scale
assessing reasons against seeking genetic testing can be found
in Table 5. Only one of 10 provided reasons against seeking
genetic testing was endorsed as “very” or “extremely
important” by greater than 20% of all respondents: “The
results could affect my health insurance.” Participants
endorsed an adjusted average of only 1.1 out of a possible
10 reasons against seeking genetic testing for AD (26%
endorsed). A significantly greater percentage of Whites
specifically selected the “effects on health insurance” item
as a reason against seeking testing in comparison to African
Americans (#2ð1Þ ¼ 3:73, p=.05). African Americans were
more likely than Whites to endorse:“There is no way to cure
or prevent AD” (#2ð1Þ ¼ 6:90, p<.05), but only 15% of
participants overall endorsed this as a reason not to pursue
testing. Overall, there were only two statistically significant
differences between African Americans and Whites in their
reasons not to pursue genetic testing. Table 6 presents a
summary of multivariate analyses examining factors associ-
ated with our outcomes of interest.
Discussion
Prior research has found race/ethnicity to be a powerful
variable in explaining differences in how people view AD and
genetic testing (Hipps et al. 2003; Peters et al. 2004;
Thompson et al. 2003); however, much of the literature
relies on responses to hypothetical testing scenarios. This is
one of the first reports to describe race group differences in
the context of a “real-life” clinical trial offering genetic
susceptibility testing to research volunteers. Our findings
suggest race group differences in knowledge and perceptions
of AD, perceived threat of developing AD, and reasons for
and against seeking genetic susceptibility testing.
In our study, African Americans were less knowledge-
able of established facts concerning AD and genetic testing
in comparison to Whites, and these findings are consistent
with similar research on other medical disorders. For
example, previous studies on cancer and hypertension show
that African Americans were less knowledgeable than
Whites about risk factors, symptoms, causes, detection
and treatment (Armstrong et al. 2002). A number of factors
(e.g. socioeconomic barriers, institutional racism, and
mistrust of the medical system) may play a role in African
Americans being less likely to access medical services,
research opportunities and medical topics in the lay
literature, thereby constraining awareness of information
about AD (Connell et al. 2001; Welsh et al. 1994). There
may also be less knowledge about AD among African
Americans because more attention is paid to conditions
such as diabetes and hypertension in the African American
community, and educational efforts and programs may
focus on these diseases rather than on AD. This lack of
knowledge may cause African Americans to make deci-
sions about genetic testing without full awareness of its
benefits, limitations and potential risks. Recent research
indicates that even though African Americans endorsed
intentions to pursue genetic testing to a greater extent than
Whites, they also shared beliefs that conflicted with this
desire (Singer et al. 2004). African Americans often express
less confidence in American institutions and less trust in
their doctors and health practitioners (Singer et al. 2004). In
any given situation, these sentiments may well override
their desire for genetic testing.
Our results also suggest that African Americans are
generally less concerned about the possibility of developing
AD in comparison to their White counterparts. This lower
level of concern is consistent with previous studies which
have shown that African Americans perceive AD as a lesser
threat than Whites (Roberts et al. 2003), and that AD poses
a lower personal burden to African American caregivers
(Lawton et al. 1992). Dementia may be considered a less
fearful condition to African Americans for several reasons
including: African Americans having greater access to
extensive support networks (e.g., family, church), a greater
Table 6 Analyses of covariance examining factors associated with knowledge and attitude scales
Combined
knowledge score
Quantified perceived
lifetime chance of
developing AD
Summed score of
reasons to pursue
genetic testing
Summed score of
reasons against
pursuing genetic
testing
I will develop
AD someday
Variable df Beta p value Beta p value Beta p value Beta p value Beta p value
Race (Black) 1 −0.645 <0.001 −7.71 0.015 0.504 0.227 0.104 0.676 −1.15 0.001
Age 1 −0.004 0.519 −0.359 0.003 −0.015 0.358 −0.010 0.313 0.040 0.004
Sex (female) 1 −0.050 0.742 4.49 0.113 0.657 0.081 −0.118 0.598 1.15 <0.001
Yrs of Educ 1 0.065 0.015 −0.036 0.942 −0.143 0.030 0.009 0.810 0.004 0.948
BAI baseline score 1 −0.019 0.184 0.883 0.001 0.072 0.041 0.039 0.065 0.072 0.026
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reliance on assuaging coping methods such as prayer, an
ability to adapt to adversity, a more positive outlook on
aging, and a greater value placed on familial roles than on
cognitive skills (Gallagher-Thompson et al. 2000). These
lower levels of concern about AD risk suggest that African
Americans may anticipate fewer negative consequences
regarding genetic testing that conveys personal risk for AD.
Interestingly, Whites in this study greatly overestimated
their lifetime risk of developing AD, a phenomenon that
was not observed in African Americans. This biased view
of personal risk may reflect Whites’ greater anxiety about
the potential consequences of AD.
In examining reasons for and against pursuing genetic
susceptibility testing, prior research on real-life “determin-
istic” DNA testing for early onset familial AD and
frontotemporal dementia revealed that the most commonly
endorsed reasons for seeking testing were for assistance
with organizing family affairs, financial planning, anxiety
relief, and other themes not directly related to medical care
(Steinbart et al. 2001). The present results similarly show
that at-risk participants pursue susceptibility testing for
practical, financial, familial and altruistic reasons. However,
in this sample, the strongest reasons participants cited for
pursuing susceptibility testing concerned medical treatment
and prevention. These results may illustrate a societal
shift from the fatalistic ideology that there is nothing that
can be done about AD to a more proactive stance where
people now believe there are, or will soon be, preventive
measures and treatments to avert or delay the onset of
this disease.
The findings also showed that on average, African
Americans endorsed a similar number of reasons to pursue
genetic testing as Whites. These results are inconsistent with
those of other related studies where race group differences in
attitudes toward genetic testing were evident (Hipps et al.
2003). The present results may be attributed to the differential
design and samples studied, as our study was querying a
sample of African Americans already self-selected on the
basis of initial interest in genetic testing (i.e., those skeptical of
or negative toward genetic testing would likely not have been
included in our sample). Studies in the breast cancer literature
have documented higher levels of interest in undergoing
genetic testing among African Americans compared to
Whites; however these studies have also referenced lower
levels of awareness of genetic testing among African
Americans (Hughes et al. 1997). Other studies have evaluated
genetic testing intentions and have shown that knowledge
and exposure to genetics is low among African Americans,
whereas expectations about the benefits of genetic testing are
high (Halbert et al. 2005). The lower knowledge scores we
observed may suggest that responses are being given by
African Americans about genetic testing for AD with
incomplete understanding of risks and benefits.
For example, a reason more commonly endorsed by
African Americans is the need to confirm feelings of
already developing AD, which medical research describes
as “anticipatory dementia” or anxiety among asymptomatic
first-degree relatives about developing the disorder (Cutler
and Hodgson 1996). Our findings extend similar research in
this area and further illustrate that some people may pursue
susceptibility testing not only to help in making practical
decisions (e.g., arranging personal affairs), but also to
answer questions of curiosity and to address fears and
anxiety about developing this disease (Roberts et al. 2003).
In this sample, 43% of African Americans said that they
pursued genetic testing in order to confirm feelings of
already developing AD, in comparison to only 20% of
Whites. Since APOE genotype cannot, in fact, provide such
confirmation, this seemingly mistaken belief about the
benefits of genetic susceptibility testing may cause African
Americans to have higher expectations of this procedure
that would not be fulfilled [Others (Hughes et al. 2003)
have also reported higher expectations about the positive
outcomes of genetic testing among African American
women]. The present finding also indicates that genetic
testing protocols for AD will have to take into account the
understandable, but potentially unfounded anxieties that
participants who seek such services may display.
At the opposite end of the spectrum, only a small
percentage of participants endorsed reasons not to pursue
testing. This is an expected finding given this was a study
of individuals who had proactively volunteered to be tested
in a research protocol. Notwithstanding this bias, the item
endorsed most frequently as a deterrent to testing (by
approximately one quarter of the sample) was “the results
could affect my health insurance,” with Whites significantly
more likely to endorse this item than African Americans. It
should be noted that these data were collected prior to
2008, when the Genetic Information Nondiscrimination Act
(GINA) was signed into law, prohibiting discrimination by
employers and health insurers based on genetic information
(Hudson et al. 2008). It remains to be seen what impact
GINA will have on the provision of genetic susceptibility
testing for AD, but our results suggest that Whites may be
more concerned about the implications of this information
on their insurance status, at least prior to formal education
on this topic. Long term care coverage currently remains
very expensive and if genetic testing for AD becomes more
customary, insurance companies may attempt to protect
themselves from adverse selection by requesting genetic
information (Zick et al. 2005).
These differences in attitudes towards genetic testing may
represent differences in knowledge about genetic testing and
related issues that were not accounted for by the brief
measures used in this study. A recent public opinion survey
suggested African Americans are in fact, more concerned
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about the possible misuses of genetic information and are
more concerned about privacy with reference to the govern-
ment (Singer et al. 2004). A recent study in Detroit found that
even among those with access to health care, African
Americans were less likely to participate in a research
project offering multiplex genetic susceptibility testing and
education about risk of eight common health conditions
(Hensley Alford et al. 2011). Such findings suggest that
awareness of the potential risks and limitations of genetic
testing for AD may make reasons against seeking genetic
testing among African Americans more pronounced.
Study Limitations
There are several limitations of this study. Our sample was
predominantly White, female, highly educated and of high
socioeconomic status. Importantly, our results reflect those of
persons who were willing, and in some cases, aggressively
volunteered, to pursue genetic testing for AD. Our statistical
adjustment for education did not take into account quality of
education, which often differs across and within racial and
ethnic groups. Furthermore, reported race group identity may
be a proxy for numerous social factors that were not assessed
in this study. For the majority of questions, we used a forced-
choice answer format that might have affected our data, as the
questions might have been unclear and the cultural validity of
certain items might have varied. For the few questions, where
“I don’t know” or “undecided” was an option, we found a
greater percentage of African Americans answered with one
of these choices. If we had provided this option more often,
particularly with the knowledge questions, our results might
have been different.
Practice Implications
The results of this study suggest a potential need for increased
outreach and education about AD genetics for African
Americans. Even among this well-educated sample in which
mean education level was equivalent to a bachelor’s degree,
many participants demonstrated limited awareness of impor-
tant facts surrounding AD and genetic testing. Existing cancer
research has demonstrated that education efforts that increase
general knowledge are directly associated with health behav-
ior changes and better decision-making (Lerman et al. 1999;
Millon-Underwood and Sanders 1990). The addition of
personalized genetic counseling may lead to greater
increases in awareness of limitations and risks of testing
compared with education alone. Our results suggest that
culturally sensitive educational initiatives should be
considered for genetic testing of late-onset Alzheimer’s
disease.
Research Recommendations
The results of this study suggest that while African Americans
may be less concerned about AD, in our sample of research
volunteers they endorsed just as many reasons for pursuing
genetic susceptibility testing as Whites. Due to structural
inequalities in society and the U.S. healthcare system, African
Americans may be less knowledgeable about the inherent
limitations of genetic testing and may therefore be less aware
of potential negative consequences of testing. Future analyses
are planned to examine whether the knowledge levels and
attitudes of both groups towards genetic testing persist after
they receive formal education and counseling and after they
receive their personal AD risk estimates.
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